A single-molecule triple agonist of the GLP-1, GIP, and glucagon receptors — studied for metabolic regulation, appetite signaling, and energy balance in research models.
Independently 8× tested by a US ISO/IEC 17025 lab.
IC-3 RT is a single-molecule triple agonist of the GLP-1, GIP, and glucagon receptors, studied for metabolic regulation, appetite signaling, and energy balance in research models.
Each batch of IC-3 RT is tested by a U.S.-based, ISO/IEC 17025-accredited laboratory across the following verification protocols.
Identity Confirmation
Compound-specific chromatographic fingerprinting (HPLC) that matches sample retention time and peak profile against certified reference standards, verifying the sample matches the expected compound.
Purity Analysis (≥99% by HPLC)
High-performance liquid chromatography profiling to confirm purity of 99% or greater.
Sterility Screening
Microbial contamination testing on multiple vials per lot, using a DNA-based microarray platform for rapid detection of a broad panel of contaminants to confirm the absence of microbial growth under validated laboratory methods.
Endotoxin Assessment (USP <85>)
Kinetic chromogenic LAL screening for bacterial endotoxin quantitation, performed on multiple vials per lot as an added contamination control beyond microbial testing. Results are reported in EU/mg with full method documentation on the Certificate of Analysis.
Heavy Metal Analysis (ICP-MS)
Multi-element screening for trace elemental contaminants and residual metals introduced during solid-phase peptide synthesis (including copper, zinc, iron, and lead), performed by ICP-MS in accordance with ICH Q3D elemental impurity guidelines.
Conformity Verification
Confirmation of consistent purity and content across multiple vials per lot, ensuring uniformity and reproducibility throughout each lot.
Fill Weight Confirmation
Net content verification to confirm lot consistency.
Fentanyl Screening
Contamination testing to verify that research compounds and peptides are free of fentanyl.
Peer-reviewed literature for this triple-hormone-receptor agonist (LY3437943, CAS 2381089-83-2). Each links to its source record.
Laboratory and preclinical literature on this compound can be found through independent public research databases. This is provided as research context only — not medical advice, and not a claim that any specific paper exists or applies to this product.
Sold for in vitro research and educational purposes only. Not evaluated by the FDA or any regulatory authority; not intended to diagnose, treat, cure, or prevent any disease. Use is restricted to authorized research personnel or institutions in compliance with all applicable local, state, and federal law. All liability for handling, use, or misuse rests solely with the buyer — Ivory Compounds and its affiliates are not liable for any misuse or mishandling.